A new case report published in Annals of Internal Medicine describes a novel approach for treating fibrosing mediastinitis ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

“Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory ...

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...

The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in ...

Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...

Incyte has won European Commission expanded approval of its Minjuvi cancer drug for certain patients with one of the most-common subtypes of non-Hodgkin lymphoma.

Incyte (INCY) announced that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

Studies presented at the ASH Annual Meeting 2025 highlighted a novel prognostic approach and emerging treatment strategies in lymphoma.